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Summary: Despite the early containment measures of the DRC government, COVID-19 pandemic has 
spread in Kinshasa with an overall 16.6% SARS-CoV-2 seroprevalence after the peak of the first wave, 





















Background: On October, 2020, after the first wave of COVID-19, only 8290 confirmed cases were 
reported in Kinshasa, Democratic Republic of the Congo, but the real prevalence remains unknown. 
To guide public health policies, we aimed to describe the prevalence of SARS-CoV-2 IgG antibodies in 
the general population in Kinshasa. 
Methods: We conducted a cross-sectional, household-based serosurvey between October 22, 2020, 
and November 8, 2020. Participants were interviewed at home and tested for antibodies against 
SARS-CoV-2 spike and nucleocapsid proteins in a Luminex based assay. A positive serology was 
defined as a sample that reacted with both SARS-CoV-2 proteins (100% sensitivity, 99.7% specificity). 
The overall weighted, age-standardized prevalence was estimated and the infection-to-case ratio 
was calculated to determine the proportion of undiagnosed SARS-CoV-2 infections.   
Results: A total of 1233 participants from 292 households were included (mean age, 32.4 years; 764 
[61.2%] were women). The overall weighted, age-standardized SARS-CoV-2 seroprevalence was 
16.6% (95% CI 14.0-19.5). The estimated infection-to-case ratio was 292:1. Prevalence was higher 
among participants ≥ 40 years than among those ˂18 years (21.2% vs 14.9%, respectively; p˂0.05). It 
was also higher in participants who reported hospitalization than among those who did not (29.8% 
vs 16.0%, respectively; p˂0.05). However, differences were not significant in the multivariate model 
(p=0.1). 
Conclusion: The prevalence of SARS-CoV-2 is much higher than the number of COVID-19 cases 
reported. These results justify the organization of a sequential series of serosurveys by public health 
authorities to adapt response measures to the dynamics of the pandemic. 




















COVID-19 is a highly contagious viral infection caused by SARS-CoV-2. The infection was first 
identified in December 2019 in China, but has spread extremely fast worldwide, including in Africa 
[1]. In the Democratic Republic of Congo (DRC), the first confirmed COVID-19 case was reported on 
March 10, 2020, in the capital city of Kinshasa, in a Congolese traveller who lived in Europe and had 
returned to the DRC. After the first cases, the Congolese government rapidly declared a state of 
emergency and set up a national multi-sectoral national committee to design strategies to address 
the pandemic [1]. Among the public health measures taken to control the spread of the virus,  the 
national lockdown was first imposed in Kinshasa and then across the entire country, flights from 
COVID-19–infected countries were suspended, schools and universities were closed, gatherings of 
more than 20 people were banned, and there was an obligation to wear masks in public areas [2]. 
On October 19, 2020, after the first epidemic wave (March to July), the DRC reported 11 078 
confirmed COVID-19 cases with 303 deaths. The capital city of Kinshasa represented 74% (8290) of 
all notified cases across the country [3]. COVID-19 reported cases in the DRC were much lower than 
predicted by many researchers, For example, Walker et al suggested that 70 million Africans could 
be infected by SARS-CoV-2, with more than 3 million deaths [4]. Furthermore, Wells et al estimated 
that there would be 76 213 155 infections and 319 441 deaths in the absence of physical distancing 
and any public health measures in the DRC [5]. 
Several factors may explain this glaring difference between the prediction and the number of 
COVID19 reported cases. First, the limited capacity to test for SARS-CoV-2, especially in the early 
stage of the epidemic, but gradually the daily capacity of SARS-CoV-2 polymerase chain reaction 
(PCR) testing in Kinshasa increased and reached 1000, which is still insufficient. However, there was 
no saturation of hospital reception capacities or unexplained high mortality during the same period, 
even if mortality may have been underestimated.  Some of the potential factors that could explain 



















number of asymptomatic cases, pre-existing immunity due to possible cross-reaction with other 
tropical infectious diseases or other coronaviruses, environmental factors, and early implementation 
of measures to control the disease [6, 7]. 
In the African context, and following the recommendations of the WHO,[8] population-based sero-
surveillance is important to complete data on the reported cases of SARS-CoV-2 infection in order to 
assess the real extent of the epidemic and to enable decision-makers to adjust public health 
response measures. Several serological surveys have been carried out in Africa and have shown a 
high variability of seroprevalence to SARS-CoV-2 across countries, but most were performed in 
specific population groups, such as blood donors, health care workers or other high-risk populations 
[9–11]. Apart from epidemiological factors, the difference in reported seroprevalence might be 
explained by the different types of serological assays used, especially those that are designed to 
detect a single IgG antibody, and to their target populations. We recently reported on the challenges 
of SARS-CoV-2 seroprevalence studies done in African countries with commercial tests validated in 
Europe, the USA, or Asia [12]. 
We aimed to describe the prevalence of IgG antibodies to SARS-CoV-2 in the general population of 
Kinshasa in order to understand to what extent the virus has spread after the first epidemic wave. 
Methods  
Study design and participants  
The 2020 Appui à la Riposte Africaine à l’épidémie COVID19 [Support for the African Response to 
COVID-19] (ARIACOV) survey was a household-based seroprevalence survey conducted between 
October 22, 2020 and November 8, 2020, in Kinshasa. The sampling frame used the health divisions 
of the city. Kinshasa is divided into 35 health zones, which are divided in turn into 380 health areas, 
with an estimated total population of  12 117 417 inhabitants (Système National d'Information 



















which supports 100,000 to 150,000 inhabitants and is delimited taking into account the 
geographical, cultural and economic accessibility of the population. It could be a geographical space 
contained within the limits of a territory or an administrative commune comprising a population of 
approximately 100,000 to 250,000 people in urban areas. Kinshasa is divided in 35 health zones for 
26 administrative communes based on the number of population within each administrative 
commune (unit).  A three-stage design was used to randomly select 292 households (figure S1, 
appendix p.ii). First, 14 of 35 health zones (divided into two strata corresponding to the eastern and 
western regions of the city) were selected with a probability to be selected proportional to the 
number of households in each zone. Then, within each zone, three health areas were randomly 
selected and finally eight households were selected within each health zone. To balance the groups, 
all the residents were invited to participate in the study in 50% of households and among the 
remaining 50%, only the residents aged 18 years and older were invited to participate.  
During the study, all individuals with a suspicion of COVID-19 infection were referred for PCR testing 
and patient care to the COVID-19 reference centre. All staff involved in the study were tested by PCR 
prior to the survey and followed infection, prevention and controls recommendations. Community-
based mobilization for the survey was performed in a two-step process. The study team met with 
local leaders and key stakeholders a few weeks prior to the start of the survey and also visited each 
selected cluster to directly mobilize the community about the survey. Participants were told that the 
survey was about COVID-19/SARS-CoV-2 and that they would be tested for antibodies if they agreed 
to participate. 
A smartphone application (Epicollect 5, Imperial College, London, UK) was used for listing household 
members and recording answers from the questionnaires. The individual questionnaires collected 
socioeconomic (ex. Common yard versus single family home, presence of hand washing device) and 
behavioural information (ex. absence from Kinshasa), as well as a history of symptoms associated 



















March 2020), and contact with COVID-19 patients. Interviews were done in French (official language 
of the DRC) or in any of the four national languages (Kikongo, Lingala, Swahili or Tshiluba).  
Ethics approval was obtained from the Comité d'Ethique de l’Ecole de Santé Publique de Kinshasa 
(protocol no. ESP/CE/156/2020). All adults and children (≥10 years) were informed about the study 
objectives and procedures. Adults provided written consent to participate in the study and to be 
tested for SARS-CoV-2 serology prior to starting the interview. Written parental consent and children 
ascent when ≥10 years were obtained prior to enrollment of participants ˂18 years.  
Antibody detection to SARS-CoV-2/COVID-19 
Venous blood samples (3-5 ml) were collected from eligible participants in a "red-top tube", which 
did not contain any additives and transported to the National Institute of Biomedical Research. After 
centrifugation, serum samples were aliquoted and stored at -20°C until laboratory analysis. Presence 
for antibodies to SARS-CoV-2 was done with a previously developed, highly sensitive and specific 
Luminex-based assay to simultaneously detect IgG antibodies to two viral antigens, i.e recombinant 
nucleocapsid (NC) and spike (SP) proteins derived from SARS-CoV-2, as previously described [13]. 
Results were expressed as median fluorescence intensity for 100 beads. Cutoff values were 
determined with receiver operating characteristic curve analysis from a panel of SARS-CoV-2 
negative and positive plasma samples consisting of European donors before the COVID-19 pandemic 
and hospitalized PCR-confirmed patients, respectively [13]. Specificity was validated on a panel of 
1197 samples from Africa before COVID-19 (99.7% specificity, Supplementary Table S1). A sample 
was considered positive for immunoglobulin G (IgG) against SARS-CoV-2 if it reacted simultaneously 
with NC and SP proteins. As several studies have reported a decrease in antibody levels over time, 
we considered samples with only one of two antigens above the threshold as “indeterminate” due 
to the difficulty to discriminate between antibody decline or the lower specificity of single antigen 
reaction, as often reported in samples from Africa [12, 14]. Samples with median 




















Statistical analysis was done using Stata 16 (StataCorp, College Station, TX, USA). Data were checked 
and analyzed using the svyset commands to take into account the survey design. Descriptive 
statistics were weighted to take into account the selection probability of the cluster sampling 
procedure and are presented as proportions with their 95% confidence intervals or means with 
standard deviation. The Pearson’s chi-squared test was used to compare categorical descriptive 
outcomes.  The overall prevalence estimate was weighted and age-standardized based on available 
demographic data [15]. Multivariate logistic models were used to assess the association between 
positive serology and key risk factors. Likelihood ratio tests were performed to determine the 
significance of each factor in the model. To estimate the total number of SARS-CoV-2 infections in 
the population, we multiplied the weighted, age-standardized seroprevalence by the population of 
Kinshasa at the time of the survey and divided this number by the number of reported COVID-19 
cases detected by reverse transcription-PCR on October 19, 2020, to estimate the infection-to-case 
ratio.   
Role of the funding source 
The funder of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the data in 
the study and had final responsibility for the decision to submit for publication. 
Results  
Among 292 randomly-selected households from 42 clusters, 2400 individuals were eligible; 1607 
were present at the time of the survey and 1233 (76.7%) were included in the final analysis (Figure 
1; Table 1). Of these, 1080 provided sufficient and compliant samples that were tested for anti-
SARS-CoV-2 IgG antibodies against spike and nucleocapsid proteins. Mean age participants was 32.4 



















(28.6%) in the 0-17 years age group; 764 (61.2%) were women. Most participants (72.2%) resided in 
a common yard and 668 (54.2%) did not have access to hand washing devices at home. In total, 750 
(60.8%) declared having completed secondary studies and 349 (28.3%) were pupils or students. 
Overall, 659 (53.5%) participants were from the eastern part of the city of Kinshasa.  
The overall weighted, age-standardized SARS-CoV-2 seroprevalence was 16.6% (95% CI 14.0-19.5) 
with both anti-IgG against SP and NC proteins. In addition, 17.1% (Table 2) of participants were 
considered as “indeterminate” as they were positive for SP (n = 43 (23.2%) or NC (n = 142 (76.8%) 
antibodies only. Based on the observed prevalence, we estimated that a total of 2 426 406 
(Supplementary Table S2, Supplementary Figure S1) infections most likely occurred by October 19, 
2020, in the general population of Kinshasa for 8290 official reported cases. The ratio of reported 
cases to estimated infections was 1:292. Seroprevalence was highest among participants ≥40 years 
(21.2% [95% CI 16.6-26.7]), and lowest among children between 0 and 17 years (14.9% [95% CI 10.4-
20.8]).  The observed difference was statistically significant (p<0.05) between age categories, but 
was not significant between female and male participants (17.7% [95% CI 13.9-20.9] vs 15.7% [95% 
CI 11.8-20.7], respectively) (Table 2).  
Seroprevalence was higher among participants from the western region of Kinshasa (18.5% [95% CI 
14.6-23.2]) than among those from the eastern area (14.9% [95% CI 11.8-18.8]), but the difference 
was not significant. Among participants who reported the type of residence, there was no significant 
difference between residents with a common yard (18.0% [95% CI 14.9-21.6]) and those who resided 
in a single family home (13.1% [95% 9.1-18.5]). We investigated the influence of being absent at 
home on SARS-CoV-2 seroprevalence and observed no significant difference with those still present 
since March, 2020 (13.3% [95% CI 6.8-4.6] versus 16.9% [95% CI 14.2-20.0], respectively).  
Of the 1080 participants with blood samples, 741 (68.6%) reported having at least one of the 16 
symptoms reported to be associated with COVID-19 infection. Among participants who reported no 



















and nucleocapsid proteins but no significant differences were observed among those who reported 
symptoms. We did not observe associations with a single or a combination of clinical symptoms and 
seropositivity.  We also assessed whether hospitalization could be associated with seroprevalence 
and observed that the proportion of people who admitted to have been hospitalized before the 
survey and positive for anti-SARS-CoV-2 antibodies (29.8% [95% 17.0-46.8]) was significantly higher 
compared to those who were not hospitalized (16.0% [95% CI 13.4-19.0]) (Table 3). None of the 
households reported deaths with symptoms related to COVID-19.  
We then performed multivariate analysis for all parameters with significant difference of 
seroprevalence between groups, but no significant association between age, gender and 
hospitalization with seroprevalence was found (Table 4). 
Discussion 
To our knowledge, this is the first serological survey conducted in the general population of Kinshasa 
after the first wave of the COVID-19 pandemic (March to September, 2020). The overall prevalence 
of anti-SARS-CoV-2 antibodies was 16.6%. Extrapolation to the entire population showed that 
around 2.4 million infections occurred between March and October 2020 in contrast to the 8290 PCR 
confirmed cases reported during he same period. We estimated that most cases went unnoticed, 
with only one case detected for every 292 infections.  
Seroprevalence in the DRC was higher than that reported in India, Brazil, Switzerland and 
Zambia,[16–19] but was probably linked to the different age structure or to the early stage of the 
COVID-19 pandemic, as was the case in Zambia [19]. Several other countries in Africa have reported 
varying seroprevalences eg, the prevalence was lower in Kenya, Togo and Malawi [9, 10, 20], but 
higher in Niger, the Ivory Coast and South Sudan [21–23]. This variability could be explained first by 



















the Malawi study, all the other studies reported a seroprevalence using positivity against a single 
antigen (spike or nucleocapsid). 
Although we observed a trend among age groups, seroprevalence was not significantly associated 
with age groups in our survey. Indeed, several studies have reported a different distribution of 
seroprevalence according to age, whereas others did not observe age-related differences, eg, in 
India, Brazil and Zambia, seroprevalence was similar between age groups [16, 17, 19]. However, a 
study conducted in Iran reported that the prevalence of COVID-19/SARS-CoV-2 varied by age group 
[24]. In Switzerland, seroprevalence was significantly lower among young children (5–9 years) and 
older people (≥65 years) than for other age groups [18]. Only limited data on the kinetics of 
antibodies in children are available and most tests were validated on the samples of adults with 
symptoms. However, antibody titers and kinetics in children exposed to SARS-CoV-2 are most likely 
similar to those in adults [25].  
On the basis of our pilot study that showed a low agreement between the results of commercially-
available antibody detection assays validated in Europe, the USA, or Asia on African samples, we 
recommend the use of a combination of serological tests, targeting two or more independent 
antigens in this context [12]. This is even more important with the advent of mass vaccination. 
Therefore, assuming that seropositivity against spike and nucleocapsid proteins is evidence of true 
seroconversion, we estimated the seroprevalence of antibodies against SARS-CoV-2 at 16.6%. During 
the first wave (March to September), the majority of notified PCR confirmed cases came from the 
western health zone of Kinshasa, but our study showed that seroprevalence was almost similar 
between the two geographic regions studied, thus suggesting that COVID-19 had spread throughout 
the entire city despite early government actions. Nevertheless, this high seroprevalence was not 
accompanied by higher mortality rates or saturation of hospital services. The SARS-CoV-2 virus is 
known for its ability to be transmitted to all ages, but the risk to develop a severe form increases 



















age pyramid in DRC is made up of a large base of young people, with a small top of the elderly, and 
people aged ≥65 years represent only 3% of the total population [15].  
In many studies, seroprevalence is determined using only one of the two major SARS-CoV-2 antigens 
[9–11, 16, 28]. This may lead to an overestimation due to cross-reactivity of the spike or 
nucleocapsid antibodies against other viral antigens [29] or underestimation by antibody waning 
[14]. Cross-reactivity can occur with common circulating coronaviruses, as well as other viruses such 
as dengue [29]. In contrast to anti-spike IgG antibodies, which are sustained over time, the half-life 
of the SARS-CoV-2 anti-nucleocapside IgG response seems to be shorter [14]. Seroprevalence of 
antibodies against the spike or nucleocapsid only was 17.1% in our study.  The overall 
seroprevalence in Kinshasa combining all positive and indeterminate groups could thus be higher 
and reach 32.6%. Seroprevalence based on positivity to two different SARS-CoV-2 antigens provides 
thus most likely minimal estimates, and it is probable that a proportion of the participants with 
antibodies against a single antigen also represented individuals that had a previous SARS-CoV-2 
infection. Nevertheless, most of the population from Kinshasa  remains not infected as yet and it is 
to be hoped that the spread of SARS-CoV-2 can be maintained until the herd immunity threshold is 
achieved. This estimated threshold is approximately 50% to 67%, but it could be reached faster by 
vaccination, rather than natural immunization [30, 31].  
Evidence for antibodies was found among participants who did not report having symptoms in the 
past eight months. Similar findings have been reported in many countries [19, 32]. These data 
underline the importance of testing asymptomatic individuals before travelling by air or other means 
of transport connecting different regions, even if they did not report any notion of exposure to 
SARS-CoV-2. 
Our study has several limitations. Based on the assumption that 50% of the population are ≤18 
years, we invited all residents from 50% of the households to participate in the study, while only 



















more women included which may limit the generalizability of our findings. Seroprevalence in age 
groups should be interpreted with caution as the age adjustment was done based on the 2019 
population estimation [15]. Additionally, COVID-19-related symptoms that participants had 
developed in the previous eight months were reported retrospectively, resulting in a probable recall 
bias. We also probably missed some recent infections because we only tested the presence of IgG 
antibodies as illustrated by the lower sensitivity of our assay on a panel of samples collected 
between 1-30 days after symptom onset, suggesting a possible underestimation of recent infections.  
Conclusions 
The results of the first household SARS-CoV-2 serosurvey in Kinshasa show a high seroprevalence 
and spread in both the eastern and western regions of the city, illustrating that most cases were 
undiagnosed. These results provide an excellent picture of the extent of the COVID-19 pandemic in 
Kinshasa after the peak of the first wave, as well as lessons for adjusting the countermeasures. The 
country is now facing the second wave, which is apparently more contagious than the first one. Our 
findings therefore support strengthening of the testing capacity for both symptomatic and 
asymptomatic individuals, strict application of non-pharmaceutical measures, and improvement of 
the management of severe cases. Finally, we provide evidence of the value of conducting serological 
surveys at regular intervals both extended areas of Kinshasa and in other regions of the DRC to 
better understand the trend of the pandemic, identify the population categories at highest risk for 
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Table 1. Sociodemographic characteristics of participants  
  Female  Male Total 
  n (%) n (%) n (%) 
Age 
0-17 188 (24.9) 164 (34.2) 352 (28.6) 
18-39 301 (39.9) 160 (33.4) 461 (37.4) 
≥40 265 (35.2) 155 (33.4) 420 (34.1) 
Mean age and standard deviation  33.4 ± 18.9 30.8 ± 20.2 32.4 ± 19.5 
Handwashing device 
Present 231 (48.2) 334 (44.3) 565 (45.8) 
Absent 248 (51.8) 420 (55.7) 668 (54.2) 
Type of residence 
Common courtyard 327 (68.3) 563 (74.7) 890 (72.2) 
Building 2 (0.4) 1 (0.1) 3 (0.2) 
Single-family home 145 (30.3) 184 (24.4) 329 (26.7) 
Other 5 (1.0) 6 (0.8) 110 (0.9) 
Geographical area 
East 410 (54.4) 249 (52.0) 659 (53.5) 
West 344 (45.6) 230 (48.0) 574 (46.7) 
Number of years residing in Kinshasa 
0-4 11 (2.3) 18 (2.4) 29 (2.4) 
5-9 6 (1.3) 11 (1.5) 17 (1.4) 
10-29 21 (4.4) 22 (2.9) 43 (3.5) 
30-69 19 (4.0) 30 (4.0) 49 (4.0) 
Always 417 (87.1) 665 (88.2) 1082 (87.8) 
Never 5 (1.0) 8 (1.1) 13 (1.1) 
Absence of home for more than a month since March 2020 
Yes 51 (10.7) 53 (7.0) 104 (8.4) 
No 428 (89.4) 701 (93.0) 1129 (91.6) 
Number of times absent at night since March 2020 
0 397 (82.9) 638 (84.6) 1035 (83.9) 
01-04 49 (10.2) 80 (10.6) 129 (10.4) 
05-09 10 (2.1) 14 (1.9) 24 (2.0) 
≥10 23 (4.8) 22 (2.9) 45 (3.7) 
Marital status (participants over 15 years) 
Single 184 (53.6) 273 (44.0) 457(47.4) 
Married/as a couple 139 (40.5) 239 (38.5) 378 (39.2) 
Divorced/separated 11 (3.6) 30 (13.6) 41 (4.2) 
Widower/widow 9 (2.6) 79 (12.7) 88 (9.1) 
Education (n) 
None 42 (5.6) 19 (4.0) 61 (4.95) 
Primary school 127 (16.8) 98 (20.5) 22 (18.3) 
Secondary school 496 (65.8) 254 (53.0) 750 (60.8) 




















Sales/Service 193 (25.6) 52 (10.8) 245 (19.9) 
Professional/manager 79 (10.5) 41 (8.6) 120 (9.7) 
Pupil/student 189 (25.1) 160 (33.4) 349 (28.3) 
Woman/man at home 86 (11.4) 1 (0.2) 87 (7.1) 
Construction 1 (0.1) 18 (3.8) 19 (1.5) 
Unemployed 126 (16.7) 73 (15.2) 199 (16.1) 
Other 80 (10.6) 80 (10.6) 214 (17.4) 


































    n(%) 95% CI n(%) 95% CI n(%) 95% CI 
Age               
0-17 281 39(14.9)* 10.4 - 20.8 31(10.8)* 7.2-15.9 211(75.1)* 67.7-80.1 
18-39 428 53(13.7)*  10.1 - 18.3 82(18.5)* 15.5-23.2 293(68.5)* 62.3-73.0 
≥40 371 75(21.2)* 16.6 - 26.7 72(19.9)* 15.4-25.4 224(60.4)* 52.7-64.8 
Geographic area  
East 617 79(14.9) 11.8-18.8 116(19.5) 16.0-23.6 422(68.4) 61.0-70.0 
West 463 88(18.5) 14.6-23.2 69(14.4) 11.0-18.8 306(66.1) 61.7-72.1 
Gender 
Male 417 59(15.7) 11.8 – 20.7 72(17.0) 13.1-21.9 286(68.6) 61.4-72.6 
Female  663 108(17.7) 13.9 – 20.9 113(17.2) 14.0-20.9 442(66.7) 61.2-69.9 
Handwashing device 
Yes 486 86(18.2) 14.4-22.7 94(19.1) 15.2-23.6 306(63.0) 57.4-67.8 
No 594 81(15.3) 12.0-19.3 91(15.4) 12.2-19.3 422(71.0) 64.6-73.6 
Type of residence 
Common yard 777 131(18.0) 14.9-21.6 136(17.3) 14.3-207 510(65.6) 60.6-68.7 
Single-family home 300 36(13.1) 9.1-18.5 49(16.9) 12.4-22.6 215(71.7) 63.5-75.9 
Number of years residing in Kinshasa 
0-4 24 3(18.6) 5.2-48.8 6(23.0) 8.6-48.9 15(62.5) 33.0-79.9 
5-9 16 0(0.0) 
 
3(12.5) 3.0-39.5 13(81.3) 60.5-97.0 
10-29 39 7(18.2) 7.5-37.9 5(16.7) 5.6-40.4 27(69.2) 44.0-81.6 
30-69 43 12(30.7) 16.9-49.0 7(16.4) 6.9-34.5 24(55.8) 35.4-69.7 
Always 945 144(16.2) 13.5-19.3 160(16.9) 14.2-19.9 641(67.8) 35.4-69.7 
Never 13 1(6.2) 0.7-39.3 4(38.8) 12.4-72.3 8(61.5) 23.9-82.5 
Absence of home for more than a month since March 2020 
Yes 89 10(13.3) 6.8-24.6 26(30.4)** 20.2-42.9 53(59.6) 43.8-68.1 
No 991 157(16.9) 14.2-20.0 159(15.9)** 13.4-18.9 675(68.1) 63.6-70.6 
Number of times absent at night since March 2020 
0 917 133(15.8) 13.1-19.0 148(16.0) 13.3-19.1 636(69.4) 64.5-71.8 
1-4 109 22(20.2) 12.8-30.3 27(24.2) 16.1-34.7 60(55.0) 44.6-66.1 
5-9 21 4(20.5) 6.6-48.6 5(25.6) 9.3-53.7 12(57.1) 29.3-76.8 
≥10 33 8(23.3) 10.6-43.9 5(17.3) 6.6-38.2 20(60.6) 45.3-65.6 
Marital Status (≥15 years) 
Single 448 59(14.6) 11.5 – 18.4 76(16.2) 12.5-20.7 313(69.9) 63.9-74.2 
Married/as a couple 341 61(19.5) 14.8 – 25.3 66(20.2) 15.3-25.7 214(62.8) 53.9-66.6 
Divorced/separated 37 5(11.5) 3.9-29.6 11(31.0) 6.7-26.2 19(51.4) 35.4-76.5 
Widower/widow 75 17(21.8) 12.9 – 34.5 10(13.8) 14.8-53.8 48(64.0) 50.8-76.0 
Education (n) 
None 37 8(25.3) 12.2 – 45.2 3(5.9) 1.1-26.6 26(68.7) 48.8-83.5 



















Secondary school 683 103(16.1) 13.0 – 19.8 122(17.9)  14.6-21.6 458(66.0) 61.6-70.2 
University 176 27(15.8) 10.3 - 23.5 35(19.4)  13.3-27.4 114(64.8) 55.9-72.8 
Profession (n) 
Sales/Service 220 46 (20.9) 15.2-28.0 58 (26.4) 21.1-35.3 116 (52.7) 43.6-59.2 
Professional/manager 111 16 (14.4) 9.2-27.0 19 (17.1) 9.2-27.2 68.5 (68.5) 55.4-77.6 
Pupil/student 296 40 (13.5) 10.2-20.3 35 (11.8) 8.0-16.6 221 (74.7) 67.4-79.5 
Woman/man at home 81 11 (13.6) 7.7-28.8 11 (13.6) 5.2-20.6 59 (72.8) 60.4-83.9 
Construction 19 2 (10.5) 1.7-45.1 3 (15.8) 2.4-33.0 59 (72.8) 50.2-93.7 
Unemployed 171 24 (14.0) 10.2-23.9 24 (14.0) 7.7-19.1 123 (71.9) 63.0-79.1 
Other 182 28 (15.4) 10.6-23.8 35 (19.2) 14.4-29.1 119 (65.4) 54.1-71.2 
        
OVERALL 1080 167(16.6) 14.0-19.5  185(17.13)   728(67.41)   
 
a; presence of antibodies to nucleocapsid and spike proteins. 
b; presence of antibodies to only nucleocapsid or spike protein. 
* Significant difference at 5%. 




















Table 3. Weighted proportion of prevalence to SARS-CoV-2 stratified by medical history, Kinshasa, 
DRC, 2020 
 










    n(%) 95% CI n(%) 95% CI n(%) 95% CI 
Number of symptoms  
No 324 54(18.0) 13.3-23.8 48(15.5) 11.2-21.1 222(66.5) 59.8-72.6 
1 to 2 symptoms 266 42(16.7) 11.9-22.8 57(21.2) 15.9-27.7 167(62.1) 54.9-68.8 
3 to 5 symptoms 236 38(17.5) 12.3-24.2 43(17.7) 12.6-24.2 155(64.8) 57.2-71.7 
≥5 symptoms 239 30(13.8) 9.2-20.2 35(14.1) 9.6-20.2 174(72.1) 64.7-78.4 
Symptoms  
Fever                                      
No 692 113(17.6) 14.3-21.3 123(18.1) 14.9-21.9 456(64.3) 59.9-68.5 
Yes 388 54(14.8) 11.0-19.8 62(15.3) 11.5-20.1 272(69.9) 64.1-75.1 
Chills 
No 829 142(18.3) 15.3-21.8 147(17.7) 14.7-21.0 540(64.0) 60.0-67.9 
Yes 244 24(11.2) 7.1-17.1 37(15.3)  10.6-21.7 183(73.5) 66.2-79.7 
Fatigue/asthenia 
No 844 132(16.6) 13.8-20.0 152(17.7) 14.9-21.0 560(65.6) 61.7-69.4 
Yes 232 34(16.4) 11.3-23.3 32(14.7) 9.9-21.3 166(69.9) 61.1-75.7 
Muscle pain (myalgia) 
No 832 118(14.6) 11.9-17.8 148(17.9) 15.0-21.3 566(67.5) 63.6-71.2 
Yes 240 48(23.7) 17.6-31.1 36(14.7) 10.1-20.9 156(61.7) 53.9-68.9 
Sore throat 
No 941 148(17.0) 14.2-20.2 158(16.7) 14.0-19.8 635(66.3) 62.5-69.8 
Yes 139 19(14.0) 8.4-22.4 27(19.7) 13.0-28.8 93(66.3) 56.3-75.0 
Cough  
No 791 128(17.2) 14.2-20.7 133(17.0) 14.1-20.5 530(65.7) 61.6-69.6 
Yes 289 39(14.8) 10.4-20.7 52(17.7) 12.7-23.2 198(67.8) 61.0-74.0 
Runny nose (rhinorrhea) 
No 770 122(16.7) 13.7-20.2 138(18.2) 15.2-21.8 510(65.1) 60.9-69.0 
Yes 310 45(16.3) 11.8-22.1 47(14.3)  10.3-19.5 218(69.4) 62.9-75.3 
Breathing difficulties 
No 1037 163(16.9) 14.3-19.9 176(16.9) 14.3-19.9 698(66.2) 62.6-69.5 
Yes 43 4(8.2) 2.6-23.4 9(22.5) 10.8-40.9 30(69.3) 51.0-83.0 
Loss of taste and smell (ageusia/anosmia) 
No 929 144(16.7) 13.9-19.9 162(14.5) 14.7-20.6 623(65.9) 62.1-69.5 
Yes 141 23(16.1) 10.2-24.5 23(15.3)  9.7-23.3 105(68.6)  59.2-76.7 
Chest pain 
No 849 160(16.8) 14.2-19.9 171(16.8) 14.2-19.8 678(66.4) 62.7-69.8 
Yes 160 7(13.3) 6.0-27.2 14(21.4) 12.1-25.0 50(65.3) 50.9-77.3 
Other respiratory symptoms 
No 1066 12(16.6) 14.0-19.5 182(17.1)  14.5-20.0 719(66.3) 62.8-69.6 
Yes 14 2(15.4) 3.3-49.0 3(21.4) 5.9-54.3 9(63.2) 32.5-86.0 
Anorexia 
No 917 146(16.8) 14.1-20.0 162(17.8) 15.0-21.0 609(65.4) 61.6-69.0 
Yes 163 21(15.4) 9.6-23.7 23(13.3) 8.3-20.7 119(71.3) 62.2-79.0 
Headache  
No 690 108(17.2) 13.9-21.0 121(17.5) 14.3-21.2 461(65.3) 60.9-69.5 




















No 959 156(17.4) 14.7-20.6 159(16.6) 14.0-19.7 644(66.0) 62.3-69.5 
Yes 121 11(9.7) 4.9-18.3 26(21.5) 14.0-31.6 84(68.8) 58.1-77.9 
Abdominal pain 
No 862 193(17.6) 14.7-21.0 146(17.1) 14.2-20.3 574(65.3) 61.4-69.1 
Yes 218 25(12.3) 7.8-18.8 39(17.5) 12.2-24.3 154(70.3) 62.4-77.0 
Diarrhea 
No 956 103(16.5) 13.8-19.6 161(16.9) 14.2-19.9 649(66.7) 63.0-70.2 
Yes 124 21(17.6) 10.9-27.1 24(19.1) 12.2-28.7 79(63.3) 52.8-72.7 
Hospitalization 
No 1024 153(16.0)* 13.4-19.0 177(17.3)  14.7-20.3 694(66.7) 38.6-70.0 
Yes 52 14(29.8)* 17.0-46.8 8(15.5) 7.0-30.7 30(54.8) 63.1-70.1 
 
a; presence of antibodies to nucleocapsid and spike proteins. 
b; presence of antibodies to only NC or SP protein. 




















Table 4. Association between antibodies to SARS-CoV-2 and risk factors, multivariate logistic model, 
Kinshasa, DRC, 2020 




Univariate odds ratio 
(+95% CI) 
Multivariate odds ratio 
(+95% CI) 
Gender    
   Male 59 (14.1) 1 1 
   Female 108 (16.2) 1.11 (0.73-1.68) 1.12 (0.73-1.7) 
    
Age (years)    
   0-17 39(13.9) 1 1 
   18-39 53 (12.4) 0.91 (0.53-1.55) 0.89 (0.52-2.52) 
   >40 75 (20.2) 1.54 (0.92-2.57) 
 
1.51 (0.91-2.52) 
Hospitalization    
Yes 14 (26.9) 1 1 
No 153 (14.9) 0.59 (0.30-1.16)  0.60 (0.31 – 1.17) 
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